ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,297.10
-0.21%
Dow Jones
39,869.38
-0.10%
US Dollar vs MXN
16.68639
0.03%
Brent Oil
83.22
0.02%
Bitcoin
65,290.57
0.08%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Lantheus Holdings Inc (LNTH)

  7. Lantheus Holdings Inc (LNTH) Noticias

LNTH Lantheus Holdings Inc

80.82
1.22 (1.53%)
16 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Lantheus Holdings Inc LNTH NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
1.22 1.53% 80.82 18:39:21
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
79.60 79.4599 81.25 81.10 79.60
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
15/5/202416:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/5/202415:43EDGAR2Form 8-K - Current report
15/5/202415:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/5/202415:30GLOBELantheus Announces Executive Appointments to Accelerate..
13/5/202416:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/5/202416:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/5/202416:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/5/202416:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/5/202416:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/5/202410:19EDGAR2Form 144 - Report of proposed sale of securities
02/5/202406:00GLOBELantheus Reports First Quarter 2024 Financial Results
18/4/202407:00GLOBELantheus to Host First Quarter 2024 Earnings Conference Call..
11/3/202415:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202415:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202415:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202415:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202415:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202415:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202415:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202409:46EDGAR2Form 144 - Report of proposed sale of securities
05/3/202419:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202419:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202419:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202419:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202419:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202419:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202418:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202407:30GLOBELantheus to Present at the Leerink Partners Global Biopharma..
04/3/202416:44EDGAR2Form 144 - Report of proposed sale of securities
04/3/202407:30GLOBELantheus Announces the FDA Approval of DEFINITY® (Perflutren..
28/2/202407:30GLOBELantheus Announces Promotion of Amanda Morgan to Chief..
26/2/202407:30GLOBELantheus to Present at the TD Cowen 44th Annual Health Care..
22/2/202406:49EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
22/2/202406:47EDGAR2Form 8-K - Current report
22/2/202406:00GLOBELantheus Reports Fourth Quarter and Full Year 2023 Financial..
15/2/202415:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202409:18EDGAR2Form 144 - Report of proposed sale of securities
13/2/202407:30GLOBELantheus Announces Collaboration to Provide Novel Tau..
08/2/202407:00GLOBELantheus to Host Fourth Quarter and Full Year 2023 Earnings..
26/1/202406:59EDGAR2Form 8-K - Current report
23/1/202407:00EDGAR2Form 8-K - Current report
23/1/202406:45GLOBELantheus Announces CEO Succession Plan
18/1/202415:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/1/202411:05EDGAR2Form 144 - Report of proposed sale of securities
11/1/202407:00GLOBELantheus Announces Acceptance of its First-to-File ANDA for..
09/1/202407:00GLOBELantheus Expands Radiopharmaceutical Oncology Pipeline via..
09/1/202406:57EDGAR2Form 8-K - Current report
09/1/202406:55GLOBELantheus Reports Preliminary Fiscal Year 2023 Revenue
03/1/202407:30GLOBELantheus to Present at the 42nd Annual J.P. Morgan..
19/12/202316:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Su Consulta Reciente

NASDAQ
LNTH
Lantheus
FX
NOKNZD
NOK vs NZD
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados